Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those projected in the forward-looking statements. Examples of such risks and uncertainties include whether Optimer and its partners will be able to drive further adoption in sales of DIFICID, including in new markets and territories, whether Optimer's lifecycle management initiatives will ultimately result in label expansion, risks involved in the regulatory approval process, and the uncertainty in forecasting future cash requirements and financial results.
For a full disclosure of these risks and uncertainties, please review Optimer's annual report on Form 10-K and subsequent quarterly reports on Form 10-Q as filed with the U.S. Securities and Exchange Commission.
Furthermore, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, July 31, 2012. Optimer undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. This conference call is also being webcast and will be archived on our website for 30 days after today.
Earlier today, we released financial results for the second quarter ended June 30, 2012. If you've not received this news release, or if you'd like to be added to the company's distribution list, please visit the Investor Section of our website at www.optimerpharma.com.I would now like to turn the call over to Pedro Lichtinger, Optimer's President and CEO. Pedro Lichtinger Thank you, David. July 18 mark the one year anniversary of the launch of DIFICID, and we're very proud of our accomplishments. From launch last year, to the end of June, we achieved $51.1 million in net sales and shipped almost 20,000 treatments. We surpassed our 12-month sales gross established with Cubist. And so, Cubist has earned a $5 million bonus payment and a portion of the gross margin above that threshold.